Last reviewed · How we verify

Bupivacaine and Dexamethasone Injection

Colette Curtis MD · FDA-approved active Small molecule

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and swelling at the injection site.

Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and swelling at the injection site. Used for Local and regional anesthesia with anti-inflammatory adjuvant therapy, Nerve blocks and infiltration anesthesia.

At a glance

Generic nameBupivacaine and Dexamethasone Injection
Also known asDecadron, bupivacaine
SponsorColette Curtis MD
Drug classLocal anesthetic with corticosteroid adjuvant
TargetVoltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaPain Management / Regional Anesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that inhibits sodium influx into nerve cells, preventing depolarization and blocking pain signal transmission. Dexamethasone, a corticosteroid, suppresses inflammatory responses and reduces edema, potentially prolonging anesthetic duration and improving pain relief. This combination is used to enhance and extend the analgesic effect of local anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: